Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats
Background/aims: Lipopolysaccharide (LPS) induces liver injury which is associated with upregulated endothelin (ET)-1 production. The aim of this study was to investigate the effects of tezosentan, a non-selective ETA and ETB receptor antagonist, in LPS challenged rats with cirrhosis. Methods: Rats...
Gespeichert in:
| Veröffentlicht in: | Gut 2004-12, Vol.53 (12), p.1844-1849 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1849 |
|---|---|
| container_issue | 12 |
| container_start_page | 1844 |
| container_title | Gut |
| container_volume | 53 |
| creator | Urbanowicz, W Sogni, P Moreau, R Tazi, K A Barriere, E Poirel, O Martin, A Guimont, M C Cazals-Hatem, D Lebrec, D |
| description | Background/aims: Lipopolysaccharide (LPS) induces liver injury which is associated with upregulated endothelin (ET)-1 production. The aim of this study was to investigate the effects of tezosentan, a non-selective ETA and ETB receptor antagonist, in LPS challenged rats with cirrhosis. Methods: Rats with cirrhosis received LPS and then tezosentan or placebo one hour later. Four hours after LPS administration, rats were killed to measure serum transaminase activity and plasma tumour necrosis factor α (TNF-α) levels. Hepatic inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO), a marker of neutrophil infiltration, and cyclooxygenase (COX)-2 expression were also measured. Results: LPS administration significantly decreased arterial pressure and significantly increased plasma endothelin levels. Following LPS and tezosentan administration, serum aspartate aminotransferase and alanine aminotransferase activities were similar to those in the control group while they were increased by more than 700% with LPS alone. Plasma TNF-α levels were significantly lower in rats receiving LPS and tezosentan (182 (38) pg/ml) compared with those receiving LPS alone (821 (212) pg/ml). Tezosentan significantly decreased hepatic MPO activity and hepatic neutrophils but had no effect on LPS induced iNOS or COX-2. Survival rate was significantly higher in rats receiving LPS plus tezosentan (80%) than in rats receiving LPS alone (50%). Conclusion: In LPS challenged cirrhotic rats, tezosentan administration prevents LPS induced liver injury by decreasing intrahepatic neutrophil infiltration. In addition, tezosentan increases survival in these rats. |
| doi_str_mv | 10.1136/gut.2003.036517 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1774327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4014110511</sourcerecordid><originalsourceid>FETCH-LOGICAL-b617t-dc5b0948e7a74edab66152ca7f7662ce5955d8fba239a49f78ba08ff5566e8643</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS0EotPCmh2KhGCBmqkf8SObSmhUymMEmwEkNpbjODMeEnuwnarl1-MhoxbYdHUt3-8-zj0APENwjhBhZ-sxzTGEZA4Jo4g_ADNUMVESLMRDMIMQ8ZLyqj4CxzFuIYRC1OgxOEKUVphiNgN2ZX75aFxS7rRQrjCu9WljeuuKYLTZJR_yd1Jr72xMp0VvB5tiDlcmFNZtx3CTw1Tmr_NLb1TfG7c2baFtCBufrC6CSvEJeNSpPpqnh3gCvry9WC3elcvPl-8Xb5ZlwxBPZatpA-tKGK54ZVrVMIYo1op3nDGsDa0pbUXXKExqVdUdF42CousoZcwIVpETcD713Y3NYFqdtQXVy12wgwo30isr_804u5FrfyUR5xXBPDd4dWgQ_M_RxCQHG7Xpe-WMH6NkHLIa4-peENV1hShEGXzxH7j1Y3D5CvuhNcGU_aHOJkoHH2Mw3e3OCMq92zK7Lfduy8ntXPH8b6l3_MHeDLw8ACpq1XdBOW3jHcdIPjWFmSsnLntsrm_zKvzIagmn8tPXhVx9uyQflvCj_J751xPfDNt7t_wNhZjReA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779325601</pqid></control><display><type>article</type><title>Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Urbanowicz, W ; Sogni, P ; Moreau, R ; Tazi, K A ; Barriere, E ; Poirel, O ; Martin, A ; Guimont, M C ; Cazals-Hatem, D ; Lebrec, D</creator><creatorcontrib>Urbanowicz, W ; Sogni, P ; Moreau, R ; Tazi, K A ; Barriere, E ; Poirel, O ; Martin, A ; Guimont, M C ; Cazals-Hatem, D ; Lebrec, D</creatorcontrib><description>Background/aims: Lipopolysaccharide (LPS) induces liver injury which is associated with upregulated endothelin (ET)-1 production. The aim of this study was to investigate the effects of tezosentan, a non-selective ETA and ETB receptor antagonist, in LPS challenged rats with cirrhosis. Methods: Rats with cirrhosis received LPS and then tezosentan or placebo one hour later. Four hours after LPS administration, rats were killed to measure serum transaminase activity and plasma tumour necrosis factor α (TNF-α) levels. Hepatic inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO), a marker of neutrophil infiltration, and cyclooxygenase (COX)-2 expression were also measured. Results: LPS administration significantly decreased arterial pressure and significantly increased plasma endothelin levels. Following LPS and tezosentan administration, serum aspartate aminotransferase and alanine aminotransferase activities were similar to those in the control group while they were increased by more than 700% with LPS alone. Plasma TNF-α levels were significantly lower in rats receiving LPS and tezosentan (182 (38) pg/ml) compared with those receiving LPS alone (821 (212) pg/ml). Tezosentan significantly decreased hepatic MPO activity and hepatic neutrophils but had no effect on LPS induced iNOS or COX-2. Survival rate was significantly higher in rats receiving LPS plus tezosentan (80%) than in rats receiving LPS alone (50%). Conclusion: In LPS challenged cirrhotic rats, tezosentan administration prevents LPS induced liver injury by decreasing intrahepatic neutrophil infiltration. In addition, tezosentan increases survival in these rats.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>EISSN: 1458-3288</identifier><identifier>DOI: 10.1136/gut.2003.036517</identifier><identifier>PMID: 15542526</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Animals ; Bile ; Biological and medical sciences ; cirrhosis ; COX ; cyclooxygenase ; cyclooxygenase 2 ; Cytokines ; EGTA ; endothelin ; Endothelin Receptor Antagonists ; Endothelins - blood ; Endotoxemia - complications ; Endotoxemia - drug therapy ; Endotoxemia - metabolism ; endotoxin ; Enzymes ; ethylene glyco-bi-aminoethylether-N-tetraacetic acid ; Gangrene ; Gastroenterology. Liver. Pancreas. Abdomen ; Histology ; inducible nitric oxide synthase ; iNOS ; Laboratories ; lipopolysaccharide ; Lipopolysaccharides ; Liver ; Liver - enzymology ; Liver cirrhosis ; Liver Cirrhosis - complications ; Liver Cirrhosis - metabolism ; liver damage ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; LPS ; Male ; Medical sciences ; Mortality ; MPO ; myeloperoxidase ; Neutrophil Infiltration - drug effects ; Neutrophils ; nitric oxide ; Nitric Oxide Synthase - metabolism ; Nitric Oxide Synthase Type II ; Other diseases. Semiology ; PBS ; Peroxidase - metabolism ; phenylmethyl-sulphonyl flupride ; phosphate buffered saline ; Plasma ; PMSF ; Proteins ; Pyridines - therapeutic use ; rat ; Rats ; Rats, Sprague-Dawley ; Rodents ; SDS ; serum transaminase ; sodium dodecyl sulphate ; Tetrazoles - therapeutic use ; tezosentan ; TNF-α ; Transaminases - blood ; Tumor Necrosis Factor-alpha - metabolism ; Tumor necrosis factor-TNF ; tumour necrosis factor α ; Vasodilator Agents - therapeutic use</subject><ispartof>Gut, 2004-12, Vol.53 (12), p.1844-1849</ispartof><rights>Copyright 2004 by Gut</rights><rights>2005 INIST-CNRS</rights><rights>Copyright: 2004 Copyright 2004 by Gut</rights><rights>Copyright © Copyright 2004 by Gut 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b617t-dc5b0948e7a74edab66152ca7f7662ce5955d8fba239a49f78ba08ff5566e8643</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774327/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774327/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16309450$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15542526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Urbanowicz, W</creatorcontrib><creatorcontrib>Sogni, P</creatorcontrib><creatorcontrib>Moreau, R</creatorcontrib><creatorcontrib>Tazi, K A</creatorcontrib><creatorcontrib>Barriere, E</creatorcontrib><creatorcontrib>Poirel, O</creatorcontrib><creatorcontrib>Martin, A</creatorcontrib><creatorcontrib>Guimont, M C</creatorcontrib><creatorcontrib>Cazals-Hatem, D</creatorcontrib><creatorcontrib>Lebrec, D</creatorcontrib><title>Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats</title><title>Gut</title><addtitle>Gut</addtitle><description>Background/aims: Lipopolysaccharide (LPS) induces liver injury which is associated with upregulated endothelin (ET)-1 production. The aim of this study was to investigate the effects of tezosentan, a non-selective ETA and ETB receptor antagonist, in LPS challenged rats with cirrhosis. Methods: Rats with cirrhosis received LPS and then tezosentan or placebo one hour later. Four hours after LPS administration, rats were killed to measure serum transaminase activity and plasma tumour necrosis factor α (TNF-α) levels. Hepatic inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO), a marker of neutrophil infiltration, and cyclooxygenase (COX)-2 expression were also measured. Results: LPS administration significantly decreased arterial pressure and significantly increased plasma endothelin levels. Following LPS and tezosentan administration, serum aspartate aminotransferase and alanine aminotransferase activities were similar to those in the control group while they were increased by more than 700% with LPS alone. Plasma TNF-α levels were significantly lower in rats receiving LPS and tezosentan (182 (38) pg/ml) compared with those receiving LPS alone (821 (212) pg/ml). Tezosentan significantly decreased hepatic MPO activity and hepatic neutrophils but had no effect on LPS induced iNOS or COX-2. Survival rate was significantly higher in rats receiving LPS plus tezosentan (80%) than in rats receiving LPS alone (50%). Conclusion: In LPS challenged cirrhotic rats, tezosentan administration prevents LPS induced liver injury by decreasing intrahepatic neutrophil infiltration. In addition, tezosentan increases survival in these rats.</description><subject>Animals</subject><subject>Bile</subject><subject>Biological and medical sciences</subject><subject>cirrhosis</subject><subject>COX</subject><subject>cyclooxygenase</subject><subject>cyclooxygenase 2</subject><subject>Cytokines</subject><subject>EGTA</subject><subject>endothelin</subject><subject>Endothelin Receptor Antagonists</subject><subject>Endothelins - blood</subject><subject>Endotoxemia - complications</subject><subject>Endotoxemia - drug therapy</subject><subject>Endotoxemia - metabolism</subject><subject>endotoxin</subject><subject>Enzymes</subject><subject>ethylene glyco-bi-aminoethylether-N-tetraacetic acid</subject><subject>Gangrene</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Histology</subject><subject>inducible nitric oxide synthase</subject><subject>iNOS</subject><subject>Laboratories</subject><subject>lipopolysaccharide</subject><subject>Lipopolysaccharides</subject><subject>Liver</subject><subject>Liver - enzymology</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - metabolism</subject><subject>liver damage</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>LPS</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>MPO</subject><subject>myeloperoxidase</subject><subject>Neutrophil Infiltration - drug effects</subject><subject>Neutrophils</subject><subject>nitric oxide</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Other diseases. Semiology</subject><subject>PBS</subject><subject>Peroxidase - metabolism</subject><subject>phenylmethyl-sulphonyl flupride</subject><subject>phosphate buffered saline</subject><subject>Plasma</subject><subject>PMSF</subject><subject>Proteins</subject><subject>Pyridines - therapeutic use</subject><subject>rat</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Rodents</subject><subject>SDS</subject><subject>serum transaminase</subject><subject>sodium dodecyl sulphate</subject><subject>Tetrazoles - therapeutic use</subject><subject>tezosentan</subject><subject>TNF-α</subject><subject>Transaminases - blood</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Tumor necrosis factor-TNF</subject><subject>tumour necrosis factor α</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0017-5749</issn><issn>1468-3288</issn><issn>1458-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkUtv1DAUhS0EotPCmh2KhGCBmqkf8SObSmhUymMEmwEkNpbjODMeEnuwnarl1-MhoxbYdHUt3-8-zj0APENwjhBhZ-sxzTGEZA4Jo4g_ADNUMVESLMRDMIMQ8ZLyqj4CxzFuIYRC1OgxOEKUVphiNgN2ZX75aFxS7rRQrjCu9WljeuuKYLTZJR_yd1Jr72xMp0VvB5tiDlcmFNZtx3CTw1Tmr_NLb1TfG7c2baFtCBufrC6CSvEJeNSpPpqnh3gCvry9WC3elcvPl-8Xb5ZlwxBPZatpA-tKGK54ZVrVMIYo1op3nDGsDa0pbUXXKExqVdUdF42CousoZcwIVpETcD713Y3NYFqdtQXVy12wgwo30isr_804u5FrfyUR5xXBPDd4dWgQ_M_RxCQHG7Xpe-WMH6NkHLIa4-peENV1hShEGXzxH7j1Y3D5CvuhNcGU_aHOJkoHH2Mw3e3OCMq92zK7Lfduy8ntXPH8b6l3_MHeDLw8ACpq1XdBOW3jHcdIPjWFmSsnLntsrm_zKvzIagmn8tPXhVx9uyQflvCj_J751xPfDNt7t_wNhZjReA</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Urbanowicz, W</creator><creator>Sogni, P</creator><creator>Moreau, R</creator><creator>Tazi, K A</creator><creator>Barriere, E</creator><creator>Poirel, O</creator><creator>Martin, A</creator><creator>Guimont, M C</creator><creator>Cazals-Hatem, D</creator><creator>Lebrec, D</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>Copyright 2004 by Gut</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20041201</creationdate><title>Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats</title><author>Urbanowicz, W ; Sogni, P ; Moreau, R ; Tazi, K A ; Barriere, E ; Poirel, O ; Martin, A ; Guimont, M C ; Cazals-Hatem, D ; Lebrec, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b617t-dc5b0948e7a74edab66152ca7f7662ce5955d8fba239a49f78ba08ff5566e8643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Bile</topic><topic>Biological and medical sciences</topic><topic>cirrhosis</topic><topic>COX</topic><topic>cyclooxygenase</topic><topic>cyclooxygenase 2</topic><topic>Cytokines</topic><topic>EGTA</topic><topic>endothelin</topic><topic>Endothelin Receptor Antagonists</topic><topic>Endothelins - blood</topic><topic>Endotoxemia - complications</topic><topic>Endotoxemia - drug therapy</topic><topic>Endotoxemia - metabolism</topic><topic>endotoxin</topic><topic>Enzymes</topic><topic>ethylene glyco-bi-aminoethylether-N-tetraacetic acid</topic><topic>Gangrene</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Histology</topic><topic>inducible nitric oxide synthase</topic><topic>iNOS</topic><topic>Laboratories</topic><topic>lipopolysaccharide</topic><topic>Lipopolysaccharides</topic><topic>Liver</topic><topic>Liver - enzymology</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - metabolism</topic><topic>liver damage</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>LPS</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>MPO</topic><topic>myeloperoxidase</topic><topic>Neutrophil Infiltration - drug effects</topic><topic>Neutrophils</topic><topic>nitric oxide</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Other diseases. Semiology</topic><topic>PBS</topic><topic>Peroxidase - metabolism</topic><topic>phenylmethyl-sulphonyl flupride</topic><topic>phosphate buffered saline</topic><topic>Plasma</topic><topic>PMSF</topic><topic>Proteins</topic><topic>Pyridines - therapeutic use</topic><topic>rat</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Rodents</topic><topic>SDS</topic><topic>serum transaminase</topic><topic>sodium dodecyl sulphate</topic><topic>Tetrazoles - therapeutic use</topic><topic>tezosentan</topic><topic>TNF-α</topic><topic>Transaminases - blood</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Tumor necrosis factor-TNF</topic><topic>tumour necrosis factor α</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Urbanowicz, W</creatorcontrib><creatorcontrib>Sogni, P</creatorcontrib><creatorcontrib>Moreau, R</creatorcontrib><creatorcontrib>Tazi, K A</creatorcontrib><creatorcontrib>Barriere, E</creatorcontrib><creatorcontrib>Poirel, O</creatorcontrib><creatorcontrib>Martin, A</creatorcontrib><creatorcontrib>Guimont, M C</creatorcontrib><creatorcontrib>Cazals-Hatem, D</creatorcontrib><creatorcontrib>Lebrec, D</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Urbanowicz, W</au><au>Sogni, P</au><au>Moreau, R</au><au>Tazi, K A</au><au>Barriere, E</au><au>Poirel, O</au><au>Martin, A</au><au>Guimont, M C</au><au>Cazals-Hatem, D</au><au>Lebrec, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>53</volume><issue>12</issue><spage>1844</spage><epage>1849</epage><pages>1844-1849</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><eissn>1458-3288</eissn><coden>GUTTAK</coden><abstract>Background/aims: Lipopolysaccharide (LPS) induces liver injury which is associated with upregulated endothelin (ET)-1 production. The aim of this study was to investigate the effects of tezosentan, a non-selective ETA and ETB receptor antagonist, in LPS challenged rats with cirrhosis. Methods: Rats with cirrhosis received LPS and then tezosentan or placebo one hour later. Four hours after LPS administration, rats were killed to measure serum transaminase activity and plasma tumour necrosis factor α (TNF-α) levels. Hepatic inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO), a marker of neutrophil infiltration, and cyclooxygenase (COX)-2 expression were also measured. Results: LPS administration significantly decreased arterial pressure and significantly increased plasma endothelin levels. Following LPS and tezosentan administration, serum aspartate aminotransferase and alanine aminotransferase activities were similar to those in the control group while they were increased by more than 700% with LPS alone. Plasma TNF-α levels were significantly lower in rats receiving LPS and tezosentan (182 (38) pg/ml) compared with those receiving LPS alone (821 (212) pg/ml). Tezosentan significantly decreased hepatic MPO activity and hepatic neutrophils but had no effect on LPS induced iNOS or COX-2. Survival rate was significantly higher in rats receiving LPS plus tezosentan (80%) than in rats receiving LPS alone (50%). Conclusion: In LPS challenged cirrhotic rats, tezosentan administration prevents LPS induced liver injury by decreasing intrahepatic neutrophil infiltration. In addition, tezosentan increases survival in these rats.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>15542526</pmid><doi>10.1136/gut.2003.036517</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-5749 |
| ispartof | Gut, 2004-12, Vol.53 (12), p.1844-1849 |
| issn | 0017-5749 1468-3288 1458-3288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1774327 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Bile Biological and medical sciences cirrhosis COX cyclooxygenase cyclooxygenase 2 Cytokines EGTA endothelin Endothelin Receptor Antagonists Endothelins - blood Endotoxemia - complications Endotoxemia - drug therapy Endotoxemia - metabolism endotoxin Enzymes ethylene glyco-bi-aminoethylether-N-tetraacetic acid Gangrene Gastroenterology. Liver. Pancreas. Abdomen Histology inducible nitric oxide synthase iNOS Laboratories lipopolysaccharide Lipopolysaccharides Liver Liver - enzymology Liver cirrhosis Liver Cirrhosis - complications Liver Cirrhosis - metabolism liver damage Liver. Biliary tract. Portal circulation. Exocrine pancreas LPS Male Medical sciences Mortality MPO myeloperoxidase Neutrophil Infiltration - drug effects Neutrophils nitric oxide Nitric Oxide Synthase - metabolism Nitric Oxide Synthase Type II Other diseases. Semiology PBS Peroxidase - metabolism phenylmethyl-sulphonyl flupride phosphate buffered saline Plasma PMSF Proteins Pyridines - therapeutic use rat Rats Rats, Sprague-Dawley Rodents SDS serum transaminase sodium dodecyl sulphate Tetrazoles - therapeutic use tezosentan TNF-α Transaminases - blood Tumor Necrosis Factor-alpha - metabolism Tumor necrosis factor-TNF tumour necrosis factor α Vasodilator Agents - therapeutic use |
| title | Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T22%3A24%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tezosentan,%20an%20endothelin%20receptor%20antagonist,%20limits%20liver%20injury%20in%20endotoxin%20challenged%20cirrhotic%20rats&rft.jtitle=Gut&rft.au=Urbanowicz,%20W&rft.date=2004-12-01&rft.volume=53&rft.issue=12&rft.spage=1844&rft.epage=1849&rft.pages=1844-1849&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gut.2003.036517&rft_dat=%3Cproquest_pubme%3E4014110511%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779325601&rft_id=info:pmid/15542526&rfr_iscdi=true |